CD274 and head and neck squamous cell carcinoma: The blockade of the PD-1 receptor or its ligand PD-L1 is one of the novel approaches for cancer immunotherapy that induced unprecedented objective response in up to 20- 30% of HNSCC patients [4, 39, 43, 44].